Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application

Zhenyu Yue1

  • 1Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA. zhenyu.yue@mssm.edu

Insights

Genetic mouse models of Leucine-Rich Repeat kinase 2 (LRRK2) mutations offer insights into Parkinson's disease (PD) pathogenesis. These models aid in understanding early PD progression and identifying drug targets for LRRK2 kinase inhibitors.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Missense mutations in Leucine-Rich Repeat kinase 2 (LRRK2) are a primary genetic cause of Parkinson's disease (PD).
  • Understanding LRRK2's role is crucial for developing effective PD therapeutics.

Purpose of the Study:

  • To summarize recent findings from genetic LRRK2 mouse models.
  • To discuss the utility of these models in understanding early PD and identifying drug targets.

Main Methods:

  • Development of genetic mouse models using various genetic approaches.
  • Analysis of PD-related pathologies and motor functions in these models.

Main Results:

  • LRRK2 mouse models exhibit some PD-related pathologies like impaired dopamine transmission and tauopathies.
  • These models demonstrate abnormal motor functions but lack substantial PD neuropathology and clinical syndromes.
  • Ongoing research illuminates LRRK2 cellular functions and pathogenic pathways.

Conclusions:

  • Genetic LRRK2 models are valuable tools for studying pre-symptomatic PD progression.
  • These models assist in identifying and validating drug targets for PD.
  • The models can be applied to chemical screening for LRRK2 kinase inhibitors.